Understanding cachexia as a cancer metabolism syndrome
Author:
Top Cited Papers
Open Access
- 22 February 2016
- journal article
- review article
- Published by Springer Nature in Oncogenesis
- Vol. 5 (2) , e200
Abstract
Metabolic reprogramming occurs in tumors to foster cancer cell proliferation, survival and metastasis, but as well at a systemic level affecting the whole organism, eventually leading to cancer cachexia. Indeed, as cancer cells rely on external sources of nitrogen and carbon skeleton to grow, systemic metabolic deregulation promoting tissue wasting and metabolites mobilization ultimately supports tumor growth. Cachectic patients experience a wide range of symptoms affecting several organ functions such as muscle, liver, brain, immune system and heart, collectively decreasing patients’ quality of life and worsening their prognosis. Moreover, cachexia is estimated to be the direct cause of at least 20% of cancer deaths. The main aspect of cachexia syndrome is the unstoppable skeletal muscle and fat storage wasting, even with an adequate caloric intake, resulting in nutrient mobilization – both directly as lipid and amino acids and indirectly as glucose derived from the exploitation of liver gluconeogenesis – that reaches the tumor through the bloodstream. From a metabolic standpoint, cachectic host develops a wide range of dysfunctions, from increased insulin and IGF-1 resistance to induction of mitochondrial uncoupling proteins and fat tissue browning resulting in an increased energy expenditure and heat generation, even at rest. For a long time, cachexia has been merely considered an epiphenomenon of end-stage tumors. However, in specific tumor types, such as pancreatic cancers, it is now clear that patients present markers of tissue wasting at a stage in which tumor is not yet clinically detectable, and that host amino acid supply is required for tumor growth. Indeed, tumor cells actively promote tissue wasting by secreting specific factors such as parathyroid hormone-related protein and micro RNAs. Understanding the molecular and metabolic mediators of cachexia will not only advance therapeutic approaches against cancer, but also improve patients’ quality of life.Keywords
This publication has 195 references indexed in Scilit:
- Why cachexia kills: examining the causality of poor outcomes in wasting conditionsJournal of Cachexia, Sarcopenia and Muscle, 2013
- TSC22D4 is a molecular output of hepatic wasting metabolismEMBO Molecular Medicine, 2013
- Cancer cachexia: impact, mechanisms and emerging treatmentsJournal of Cachexia, Sarcopenia and Muscle, 2012
- MYC on the Path to CancerCell, 2012
- Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver DiseaseCell Metabolism, 2011
- Gut barrier dysfunction in the ApcMin/+ mouse model of colon cancer cachexiaBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- The role of insulin resistance in the development of muscle wasting during cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2011
- The cachexia score (CASCO): a new tool for staging cachectic cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- NF-κB Inhibition Protects against Tumor-Induced Cardiac Atrophy in VivoThe American Journal of Pathology, 2011